Dr. Caroline Fichtner
Principal
About me
| Team | Life Sciences & Chemistry |
| at HTGF since | 2006 |
| my focus | Biotech, Medtech, Pre Seed & Seed // Transforming Life Science Ideas into Reality |
| my background | Doctorate in the field of biophysics, studies in biology & economics |
CV
Along with her experience in VC, biophysicist Dr Caroline Fichtner also spent many years working at the Max Planck Institute for Bioinorganic Chemistry in Mülheim an der Ruhr. At HTGF, the authorized signatory is responsible for the financing and development of technology start-ups in the life sciences field.
Four questions for …
What drives you?
To be able to accompany and support the realization of visionary ideas.
What do you like most about your job?
Cooperation with impressive personalities, but also a high degree of responsibility and independence.
What are the most important skills for founders?
Assertiveness, a sense of reality, a willingness to learn, enjoyment of implementation and a large dose of idealism.
What has changed for the better in the past five years?
I think it is positive that almost all universities are now aware of the importance of the topic of startups and are specifically promoting it.
My success stories in the HTGF portfolio
The Trans-Duodenal Barrier developed by TDC is a patented endoscopic transduodenal bypass implant for combined diabetes/obesity therapy that atraumatically prevents nutrient absorption in the duodenum and delays gastric emptying. The …
DNTOX GmbH was founded in March 2022 as a spin-off from the IUF – Leibniz Institute for Environmental Medicine Research and is based on the longstanding research work of Professor …
HBOX Therapies has developed a technology that facilitates lung-protective treatment of respiratory patients, the patented platform technology HBOX (Hyperbaric Blood Oxygenation). The management team of HBOX Therapies consists of the …
Inovedis is developing a new surgical technique for rotator cuff ruptures based on a PEEK implant. This injury is by so far the most typical shoulder injury. The patented SINEFIX …
Optimization of atrial fibrillation therapy via precise, non-thermal pulsed field ablation
Resolve Biosciences is creating solutions which offer the power of Molecular Cartography enabling scientists to gain valuable insights at subcellular resolution, across vast numbers of biomolecules (RNA, DNA, proteins) to …
stimOS develops and markets (r)evolutionary technologies that functionalize implant materials and offers these technologies to implant manufacturers. With the product lines spineFuse and smartDENT the company develops own biosimilar implant …
Thermosome is a clinical-stage drug development company focused on targeted tumor therapy combined with immune stimulation for improved cancer therapy. At its core is a novel, proprietary tumor targeting approach …
Guided to exit
KINAXO supports pharmaceutical companies in the development of targeted drugs and predictive biomarkers for personalized healthcare. Exit since Feb. 2011. Purchaser: Evotec AG
Rigontec GmbH is a preclinical biotech company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases. Rigontec’s lead compound ImOl100 targets a novel receptor of the innate immune …
Social Media & contact
LinkedIn
Dr. Caroline Fichtner
Profil